NASDAQ Framework: Viking Therapeutics Inc.
Clinical-stage biopharmaceutical company focused on metabolic disorders 1.
1: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company’s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)... View Source
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of novel therapies for metabolic and endocrine disorders. The company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently in Phase IIb clinical trials for biopsy-confirmed non-alcoholic steatohepatitis (NASH). Other notable programs include VK5211, an orally available non-steroidal selective androgen receptor modulator in Phase II clinical trials for patients recovering from non-elective hip fracture surgery, and VK2735, a novel dual agonist of the glucagon-like peptide in Phase 1 clinical trials 23.
2: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company’s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)... View Source3: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. View Source
4: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Jul 24, 2024 8:05pm Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Jul 17, 2024 8:05pm Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk MarketWatch Jul 17, 2024 4:54pm Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire Jun 24, 2024 11:33am Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire Jun 4, 2024 11:05am Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire May 30, 2024 8:03pm This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? MarketWatch Apr 13, 2024 10:23am This weight-loss ETF has performed well in its -2- MarketWatch Apr 13, 2024 10:23am Healthcare stocks fade as obesity-drug optimism fades MarketWatch Apr 2, 2024 12:59am Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy. MarketWatch Mar 28, 2024 11:09am Here's how investors can ride along as a major global commodity market shifts away from China MarketWatch Mar 2, 2024 10:17am Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount MarketWatch Mar 1, 2024 12:02pm This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag MarketWatch Feb 29, 2024 11:46pm Viking Therapeutics' promising weight-loss drug data makes the company a takeover target MarketWatch Feb 29, 2024 1:37pm Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze MarketWatch Feb 28, 2024 1:13pm Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze MarketWatch Feb 10, 2024 12:15pm What to think about 'Peak 65' MarketWatch Feb 10, 2024 9:47am Viking Therapeutics' stock rallies following early drug study data MarketWatch Oct 17, 2023 8:56pm Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes MarketWatch Aug 10, 2023 12:28pm View Source5: Jul 17, 2024 Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage... Jun 24, 2024 Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO, June 24, 2024... Jun 4, 2024 Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage... May 30, 2024 Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Apr 24, 2024 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From... View Source6: Zacks•6 hours agoThe Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards LifesciencesBoston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.Zacks•yesterdayWill These 5 Medical Stocks Surpass Q2 Earnings Forecasts?Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.Moneywise•3 days agoThis market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likesA trio of peculiar picks.Zacks•5 days agoViking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should KnowIn the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.90, marking a +1.6% move from the previous day.Zacks•5 days agoShould Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.Zacks•6 days agoWhy the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained TodayViking Therapeutics, Inc. (VKTX) reachead $50.12 at the closing of the latest trading day, reflecting a +0.56% change compared to its last close.Investor's Business Daily•7 days agoEli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug ResultsEli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.PR Newswire•7 days agoViking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2024 after the market close on Wednesday, July 24, 2024.Baystreet•9 days agoNot Sure Which Weight Loss Stock to Buy? Invest in This ETFMany healthcare companies have been eagerly developing new weight loss drugs in an effort to cash in ...Simply Wall St.•12 days agoWe're Not Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. By way of example, Viking Therapeutics... View Source7: Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 7.05 percent of Viking Therapeutics Inc shares are owned by insiders, and 73.01 percent are held by financial institutions. ZANTE GREG, the Chief Financial Officer at Viking Therapeutics Inc (VKTX) has sold 66,756 shares of firm on May 03 ’24 at a price of $74.69 against the total amount of $4.99 million. In another inside trade, Mancini Marianna, Chief Operating Officer of Viking Therapeutics Inc (NASDAQ:VKTX) sold 281,425 shares of the firm on May 01 ’24 for a total worth of $22.14 million at a price of $78.66. An inside trade which took place on Feb 09 ’24, President & CEO of Viking Therapeutics Inc Lian Brian sold 45,000 shares of firm against total price of $1.35 million at the cost of $29.90 per share. View Source8: Financial giants have made a conspicuous bearish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 10 unusual trades. View Source9: Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $45.0 to $65.0 in the last 30 days. View Source10: Morgan Stanley raised the price target for the Viking Therapeutics Inc (NASDAQ:VKTX) stock to “an Overweight”. The rating was released on June 27, 2024, according to finviz. We previously noted in another research note published on May 16, 2024 by Raymond James that upgraded the stock from an Outperform to a Strong buy with a price target of $116 for VKTX stock. The research report from Oppenheimer has reiterated the stock to Outperform, with a price target set at $138. The stock was initiated by Jefferies, who disclosed in a research note on March 07, 2024, to Buy and set the price objective to $110. In their research brief published February 28, 2024, Oppenheimer analysts reiterated the Viking Therapeutics Inc stock to Outperform with a price target of $116. View Source11: Yahoo Finance1 week agoObesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? View Source12: VKTX Earnings this Week: How Will it Perform?July 22, 2024TipRanksB. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nodJuly 12, 2024TipRanksBiotech Alert: Searches spiking for these stocks todayJuly 12, 2024TipRanksViking Therapeutics call volume above normal and directionally bullishJuly 10, 2024TipRanksOptimistic Outlook for Viking Therapeutics’ Obesity Treatments Amid Upcoming Catalysts and Regulatory ProgressJuly 4, 2024TipRanks View Source13: Viking Therapeutics reports quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%Viking reports a net loss of $22.3 million for the second quarter. View Source14: Viking Therapeutics, Inc. Pharmaceutical Manufacturing San Diego, California Intercept Pharmaceuticals Pharmaceutical Manufacturing Morristown, New Jersey Vertex Pharmaceuticals Biotechnology Research Boston, MA Akero Therapeutics Biotechnology Research South San Francisco, California Acadia Pharmaceuticals Inc. Pharmaceutical Manufacturing San Diego, California Phathom Pharmaceuticals Biotechnology Research Florham Park, New Jersey Alnylam Pharmaceuticals Biotechnology Research Cambridge, Massachusetts Jazz Pharmaceuticals Pharmaceutical Manufacturing Apellis Pharmaceuticals Biotechnology Research Waltham, MA Sage Therapeutics Biotechnology Research Cambridge, MA View Source15: The Motley Fool1 week agoIs Viking Therapeutics Stock Running Out of Steam? View Source16: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company’s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)... View Source17: The Motley Fool1 week agoBetter GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics View Source18: Tags NASDAQ:VKTX, Viking Therapeutics Inc., VKTX, VKTX stock View Source19: Viking Therapeutics Stock Climbs On Q2 EPS Beat View Source20: Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals View Source21: Viking Therapeutics, Inc. VKTX shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the key figures from the report. View Source22: The Details: Viking Therapeutics reported quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%. View Source23: VKTX Price Action: According to Benzinga Pro, Viking Therapeutics shares are up 10.10% after-hours at $55.50 at the time of publication Wednesday. View Source24: Unpacking the Latest Options Trading Trends in Viking Therapeutics View Source25: Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 View Source26: Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $65.0 for Viking Therapeutics during the past quarter. View Source27: Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today View Source28: Viking Therapeutics Option Volume And Open Interest Over Last 30 Days View Source29: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. View Source30: After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance. View Source31: Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro. View Source32: The future of Viking Therapeutics Inc (VKTX) Stock is still in tatters? View Source33: Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know View Source34: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. View Source35: What Does Viking Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock? View Source36: Unveiling Three US Growth Companies With High Insider Ownership As the Nasdaq and S&P 500 continue to set records, reflecting a robust appetite for growth among investors, it's an opportune time to explore companies where high insider ownership aligns closely with corporate ambitions and investor interests. In this context, firms with substantial insider stakes can be particularly compelling, as they often signal confidence from those who know the company best. Simply Wall St. • 19 days ago DUOL MDGL -2.14% BILI Is Madrigal Pharmaceuticals a Millionaire Maker? Its revenue ramp-up is just starting, and its market looks lucrative. Motley Fool • 23 days ago MDGL -2.14% Is Madrigal Pharmaceuticals Stock a Buy? The company could become a prominent player in the biotech industry, but that might take a while. Motley Fool • 25 days ago MDGL -2.14% Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. Motley Fool • last month MDGL -2.14% LLY Where Will Madrigal Pharmaceuticals Be in 3 Years? The coast is clear for it to grow, for now. Motley Fool • last month MDGL -2.14% Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade Madrigal Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Investor's Business Daily • last month MDGL -2.14% Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals Success isn't guaranteed, but both companies could become big winners. Motley Fool • last month VKTX +1.06% MDGL -2.14% Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigm GlobeNewswire • last month MDGL -2.14% Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH Madrigal stock plummeted Wednesday on detailed results from a study of Eli Lilly's weight-loss drug in patients with a serious liver disease. Investor's Business Daily • last month LLY MDGL -2.14% What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE:LLY) shared an abstract highlighting fibrosis results from a Phase 2 trial of tirzepatide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Tirzepatide is a key ingredient in popular Mounjaro for diabetes and Zepbound for weight loss. Other companies working on MASH candida Benzinga • last month MDGL -2.14% Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madriga GlobeNewswire • last month MDGL -2.14% Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. “The data we will be presenting at EASL further support Rezdiffra as the foundational therapy in NASH and Madrigal as the GlobeNewswire • last month MDGL -2.14% Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... On May 21, 2024, Robert Waltermire, Senior Vice President and Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), sold 1,036 shares of the company. GuruFocus.com • last month MDGL -2.14% 3 High Insider Ownership US Stocks With Up To 55% Revenue Growth Amidst a robust week for U.S. stocks, fueled by significant advancements in AI and cloud computing from major technology firms, the market landscape appears increasingly conducive to exploring growth opportunities. In this context, companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those who know the business best. Simply Wall St. • 2 months ago AVPT AVPTW MDGL -2.14% John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role Insight into Paulson's Latest 13F Filings and Its Impact on His Investment Portfolio GuruFocus.com • 2 months ago MDGL -2.14% Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript May 7, 2024 Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06. MDGL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […] Insider Monkey • 2 months ago MDGL -2.14% Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... Insights into MDGL's financial health, strategic milestones, and initial hurdles in the commercial launch of its NASH treatment. GuruFocus.com • 2 months ago MDGL -2.14% Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch First Quarter Performance Highlights and Strategic Updates GuruFocus.com • 2 months ago MDGL -2.14% Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn April 2024, product shipped and first patients received Rezdiffra, the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)On March 5, 2024, announced validation of European Medicines Agency marketing application for resmetirom Raised $690 million in gross p GlobeNewswire • 2 months ago MDGL -2.14% Madrigal Statement on the Passing of Dr. Stephen Harrison CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison. We offer our deepest condolences to Stephen’s family for their loss. Stephen was a colleague and friend to so many of us at Madrigal. He worked tirelessly to improve the lives of people with nonalcoholic steatohepatitis (NASH), and his contributions to the field will touch countless families across the globe for decades to come. So many of the recent in GlobeNewswire • 2 months ago MDGL -2.14% View Source
MEDIUM RISK
Viking Therapeutics, Inc. is currently operating at a loss, with a reported net loss of $22.3 million for the second quarter 37. However, the company has shown positive signs such as beating analyst consensus estimates for losses per share 3839 and receiving positive ratings and increased price targets from multiple financial institutions 40. Additionally, the company has promising clinical programs in various stages of development 4142. While these factors indicate potential for future growth, the current financial losses and the absence of marketed drugs place the company in a medium risk category.
Viking Therapeutics, Inc. is currently operating at a loss, with a reported net loss of $22.3 million for the second quarter 37. However, the company has shown positive signs such as beating analyst consensus estimates for losses per share 3839 and receiving positive ratings and increased price targets from multiple financial institutions 40. Additionally, the company has promising clinical programs in various stages of development 4142. While these factors indicate potential for future growth, the current financial losses and the absence of marketed drugs place the company in a medium risk category.
37: Viking Therapeutics reports quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%Viking reports a net loss of $22.3 million for the second quarter. View Source38: Viking Therapeutics reports quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%Viking reports a net loss of $22.3 million for the second quarter. View Source39: The Details: Viking Therapeutics reported quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%. View Source40: Morgan Stanley raised the price target for the Viking Therapeutics Inc (NASDAQ:VKTX) stock to “an Overweight”. The rating was released on June 27, 2024, according to finviz. We previously noted in another research note published on May 16, 2024 by Raymond James that upgraded the stock from an Outperform to a Strong buy with a price target of $116 for VKTX stock. The research report from Oppenheimer has reiterated the stock to Outperform, with a price target set at $138. The stock was initiated by Jefferies, who disclosed in a research note on March 07, 2024, to Buy and set the price objective to $110. In their research brief published February 28, 2024, Oppenheimer analysts reiterated the Viking Therapeutics Inc stock to Outperform with a price target of $116. View Source41: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company’s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)... View Source42: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. View Source
43: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Jul 24, 2024 8:05pm Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Jul 17, 2024 8:05pm Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk MarketWatch Jul 17, 2024 4:54pm Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire Jun 24, 2024 11:33am Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire Jun 4, 2024 11:05am Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire May 30, 2024 8:03pm This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? MarketWatch Apr 13, 2024 10:23am This weight-loss ETF has performed well in its -2- MarketWatch Apr 13, 2024 10:23am Healthcare stocks fade as obesity-drug optimism fades MarketWatch Apr 2, 2024 12:59am Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy. MarketWatch Mar 28, 2024 11:09am Here's how investors can ride along as a major global commodity market shifts away from China MarketWatch Mar 2, 2024 10:17am Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount MarketWatch Mar 1, 2024 12:02pm This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag MarketWatch Feb 29, 2024 11:46pm Viking Therapeutics' promising weight-loss drug data makes the company a takeover target MarketWatch Feb 29, 2024 1:37pm Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze MarketWatch Feb 28, 2024 1:13pm Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze MarketWatch Feb 10, 2024 12:15pm What to think about 'Peak 65' MarketWatch Feb 10, 2024 9:47am Viking Therapeutics' stock rallies following early drug study data MarketWatch Oct 17, 2023 8:56pm Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes MarketWatch Aug 10, 2023 12:28pm View Source44: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company’s clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH)... View Source45: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. View Source
Viking Therapeutics Inc. has a robust product roadmap and expansion strategy for 2024 through 2026, focusing on advancing its clinical programs and exploring new therapeutic areas. The company's lead candidate, VK2809, is in Phase IIb clinical trials for treating biopsy-confirmed non-alcoholic steatohepatitis (NASH) and has shown promising 52-week histologic data 4647. Additionally, Viking is developing VK5211 for patients recovering from non-elective hip fracture surgery and VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 clinical trials 48. The company also presented preclinical data on novel dual amylin and calcitonin receptor agonists, demonstrating potent body weight reductions and improved metabolic profiles 49. These efforts indicate a strategic focus on expanding their pipeline and addressing significant unmet medical needs in metabolic and endocrine disorders.
46: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Jul 24, 2024 8:05pm Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Jul 17, 2024 8:05pm Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk MarketWatch Jul 17, 2024 4:54pm Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association PR Newswire Jun 24, 2024 11:33am Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire Jun 4, 2024 11:05am Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire May 30, 2024 8:03pm This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives? MarketWatch Apr 13, 2024 10:23am This weight-loss ETF has performed well in its -2- MarketWatch Apr 13, 2024 10:23am Healthcare stocks fade as obesity-drug optimism fades MarketWatch Apr 2, 2024 12:59am Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy. MarketWatch Mar 28, 2024 11:09am Here's how investors can ride along as a major global commodity market shifts away from China MarketWatch Mar 2, 2024 10:17am Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount MarketWatch Mar 1, 2024 12:02pm This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag MarketWatch Feb 29, 2024 11:46pm Viking Therapeutics' promising weight-loss drug data makes the company a takeover target MarketWatch Feb 29, 2024 1:37pm Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze MarketWatch Feb 28, 2024 1:13pm Viking Therapeutics may offer investors a cheap entry to the weight-loss drug craze MarketWatch Feb 10, 2024 12:15pm What to think about 'Peak 65' MarketWatch Feb 10, 2024 9:47am Viking Therapeutics' stock rallies following early drug study data MarketWatch Oct 17, 2023 8:56pm Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes MarketWatch Aug 10, 2023 12:28pm View Source47: Jul 17, 2024 Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage... Jun 24, 2024 Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO, June 24, 2024... Jun 4, 2024 Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage... May 30, 2024 Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Apr 24, 2024 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From... View Source48: Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. View Source49: Jul 17, 2024 Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage... Jun 24, 2024 Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO, June 24, 2024... Jun 4, 2024 Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage... May 30, 2024 Viking Therapeutics to Participate at Upcoming Investor Conferences Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Apr 24, 2024 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From... View Source